Achromobacter xylosoxidans is an innately multidrug-resistant pathogen which is emerging in cystic fibrosis (CF) patients. We characterized a new resistance-nodulation-cell division (RND)-type multidrug efflux pump, AxyXY-OprZ. This system is responsible for the intrinsic high-level resistance of A. xylosoxidans to aminoglycosides (tobramycin, amikacin, and gentamicin). Furthermore, it can extrude cefepime, carbapenems, some fluoroquinolones, tetracyclines, and erythromycin. Some of the AxyXY-OprZ substrates are major components widely used to treat pulmonary infections in CF patients.
In this work, we studied three clinical isolates of A. xylosoxidans: AXX-A, AXX-D, and AXX-H. The strains were identified by using the API20NE system (bioMérieux, Marcy l'Etoile, France) and by sequencing of the rrs gene. Susceptibility testing was performed by Etest (bioMérieux, Marcy l'Etoile, France) and interpreted according to the breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing (http://www .eucast.org/clinical_breakpoints/). AXX-A harbors a wild-type antibiotic resistance phenotype, AXX-D an acquired resistance to ceftazidime and fluoroquinolones, and AXX-H an acquired resistance to ceftazidime, fluoroquinolones, and carbapenems (Table  1) . In these strains, we have inactivated axyY, encoding the transporter component. For this purpose, the primers INA-axyY-F and INA-axyY-R (Table 2) were designed to amplify a 755-bp region of axyY (nucleotide positions from 1696 to 2450). The PCR product was cloned into the pUC19 vector by using the In-Fusion HD cloning kit (Clontech Laboratories, Mountain View, CA) as recommended by the manufacturer. Newly constructed plasmids (pINA-axyY-AXX-A, pINA-axyY-AXX-D, and pINA-axyY-AXX-H) were used as suicide vectors. They were introduced into each strain by electroporation. Recombinant clones (axyY::Tic) named AXX-A-⌬Y, AXX-D-⌬Y, and AXX-H-⌬Y were selected on Mueller-Hinton agar plates containing 50 g/ml of ticarcillin. The disruption of axyY in each strain was confirmed by PCR and DNA sequencing (primer pairs V-INA-axyY-F/M14R and M14F/V-INA-axyY-R).
The axyY inactivation led to decreased MICs of aminoglycosides, carbapenems, cefepime, some fluoroquinolones, tetracyclines, erythromycin, and to a lesser extent, ceftazidime ( Table 1) .
The activities of all aminoglycosides tested were substantially enhanced. Susceptibility to tobramycin, amikacin, netilmicin, and gentamicin was restored for all strains. The activities of carbapenems were slightly enhanced in the mutants AXX-A-⌬Y and AXX-D-⌬Y compared with their activities in the original strains, AXX-A and AXX-D. Interestingly, the MICs of meropenem and doripenem were decreased 6-fold and 10-fold, respectively, after axyY disruption in the carbapenem-resistant strain AXX-H. This suggests that AxyXY-OprZ might lead to acquired resistance to carbapenems. Nevertheless, the MIC values of meropenem and doripenem for AXX-H-⌬Y, 2 and 1.5 g/ml, respectively, were still more elevated than those for AXX-A and AXX-D. It is likely that other mechanisms are involved in the residual carbapenem resistance of AXX-H-⌬Y. Concerning the cephalosporins, we observed that axyY inactivation resulted in a 2-fold decrease of the ceftazidime MIC, whatever the resistance level in parent strains. The activity of cefepime was partially restored in AXX-D-⌬Y but not in AXX-H-⌬Y, suggesting the association of various mechanisms of resistance. Finally, AxyXY-OprZ can also extrude tetracyclines, some fluoroquinolones, and erythromycin, which are also substrates of MexXY/OprM. The restoration of the original drug resistance phenotypes was observed in spontaneous revertants obtained by culturing mutant strains without ticarcillin.
AxyXY-OprZ from A. xylosoxidans and MexXY/OprM from P. aeruginosa have common substrates. This is consistent with the high amino acid sequence similarity observed between the transporters AxyY and MexY (73%), the transporter component being responsible for substrate recognition of the RND-type efflux systems (17) . Nevertheless, AxyXY-OprZ confers a much higher level of resistance to aminoglycosides than MexXY-OprM in wild strains. It has recently been reported for some aminoglycosideresistant strains of P. aeruginosa that mexX and mexY are linked to the oprA gene in the same operon and that MexXY can utilize either OprM or OprA to form drug efflux complexes (18) . Such an operon, including an oprA gene, has been also described in Burkholderia pseudomallei, a species intrinsically highly resistant to aminoglycosides due to expression of the AmrAB-OprA efflux pump (19) . The oprZ gene that we detected in the three strains studied (primers oprZ-F and oprZ-R) seems to be a homologue of the oprA genes from P. aeruginosa and B. pseudomallei (71% nucleotide identity and 57% amino acid identity). We plan to assess the contribution of OprZ to the high level of resistance to aminoglycosides.
In conclusion, we have demonstrated that AxyXY-OprZ confers on A. xylosoxidans a broad spectrum of antimicrobial agent resistance. The most interesting finding is that AxyXY-OprZ confers on A. xylosoxidans its intrinsic high level of resistance to aminoglycosides. Our results suggest the involvement of AxyXY-OprZ in acquired resistance to carbapenems and fluoroquinolones that are major antimicrobial components for the treatment of pulmonary infections in CF patients. This will be supported by further studies that will include more clinical isolates. 
